Information Provided By:
Fly News Breaks for February 5, 2020
Feb 5, 2020 | 16:55 EDT
Mizuho analyst Vamil Divan initiated coverage of AbbVie with a Buy rating and $96 price target. The analyst is positive on the company's acquisition of Allergan, bringing new growth drivers at an attractive price along with products early in their life cycle. The analyst adds that his proprietary surveys also show strong physician interest in Skyrizi and Rinvoq, while conversations with other physicians give him comfort in the "continued uptake of Imbruvica and Venclexta."
News For ABBV From the Last 2 Days
There are no results for your query ABBV